Incyte’s Opzelura slapped with vitiligo delay amid topical JAK’s eczema launch
Incyte’s Opzelura slapped with vitiligo delay amid topical JAK’s eczema [...]
Incyte’s Opzelura slapped with vitiligo delay amid topical JAK’s eczema [...]
UsAgainstAlzheimer’s, spending millions to bat for Biogen’s Aduhelm, launches TV [...]
AstraZeneca’s Fasenra hit with FDA rejection, falling further behind GSK’s [...]
Stevanato’s growth spree rolls on with China plant purchase, plans [...]
BeiGene, Hutchmed, Zai Lab tagged for potential US delisting under [...]
GlaxoSmithKline’s Shingrix campaign irks some in UK, but pharma adamant [...]
Amid inflation spike, execs at J&J, Bayer, GSK and more [...]
Moderna CEO Bancel set for a soft landing as his [...]
Why snackable digital experiences are the future of physician marketing [...]
Zydus hit with trio of FDA observations at Indian injectables [...]